期刊文献+
共找到1,647篇文章
< 1 2 83 >
每页显示 20 50 100
Delayed diagnosis of pulmonary tuberculosis with pleuritis due to ampicillin/sulbactam:A case report
1
作者 Munechika Hara Toshitsugu Yashiro Yasuaki Yashiro 《World Journal of Clinical Cases》 2025年第19期72-77,共6页
BACKGROUND Tuberculosis(TB)remains a global health concern despite decreasing incidence.Delayed TB diagnosis can exacerbate patient outcomes and lead to broader public health issues such as mass infections.Differentia... BACKGROUND Tuberculosis(TB)remains a global health concern despite decreasing incidence.Delayed TB diagnosis can exacerbate patient outcomes and lead to broader public health issues such as mass infections.Differentiation between TB and bacterial pneumonia is often complicated by variable clinical and radiological manifestations of TB,leading to diagnostic delays.CASE SUMMARY An 89-year-old,Japanese male patient with a history of diabetes mellitus,hypertension,and hypothyroidism presented with right-sided chest pain.Based on the elevated inflammatory response,right pleural effusion,and infiltrating shadow in the lung field,the diagnosis of right pleurisy was made and the antibiotic,ampicillin/sulbactam,was administered.The patient’s condition,inflammatory reaction,and right pleural effusion temporarily improved.However,persistent low-grade fever and malaise prompted further evaluation,revealing repeated right pleural effusion and inflammatory response.A right thoracentesis was performed;the patient was diagnosed with tuberculous pleurisy as a result of exudative effusion with lymphocyte predominance,elevated adenosine deaminase levels,and positive Mycobacterium TB polymerase chain reaction test.Anti-TB treatment,including isoniazid,rifampicin,and ethambutol was initiated,leading to significant clinical improvement.The patient successfully completed a 12-month course of TB therapy without recurrence or deterioration.CONCLUSION There are cases of TB wherein temporary improvement apparently could be shown through treatment with antimicrobial agents other than anti-TB drugs,necessitating careful evaluation in atypical cases of bacterial pneumonia. 展开更多
关键词 Antibiotics Ampicillin/sulbactam PNEUMONIA Tuberculosis Tuberculous pleuritis Case report
暂未订购
Construction of universal quantitative models for the determination of cefoperazone sodium/sulbactam sodium for injection from different manufacturers using near-infrared reflectance spectroscopy 被引量:4
2
作者 逄焕欢 冯艳春 +1 位作者 张学博 胡昌勤 《Journal of Chinese Pharmaceutical Sciences》 CAS 2008年第1期22-29,共8页
To develop near-infrared (NIR) reflectance spectroscopic methods for the quantitative analysis of cefoperazone sodium/ sulbactam sodium from different manufacturers for injection powder medicaments. Various powders ... To develop near-infrared (NIR) reflectance spectroscopic methods for the quantitative analysis of cefoperazone sodium/ sulbactam sodium from different manufacturers for injection powder medicaments. Various powders of cefoperazone sodium/ sulbactam sodium were directly analyzed by non-destructive NIR reflectance spectroscopy using the spectrometer EQUINOX55. Two quantitative methods via integrating sphere (IS) and fiberoptic probe (FOP) models were explored from 6 batches of commercial samples and 42 batches of laboratory samples at a content ranging from 30% to 70% for cefoperazone and 60% to 20% for sulbactam. The root mean square errors of cross validation (RMSECV) and the root mean square errors of prediction (RMSEP) of IS were 1.79% and 2.85%, respectively, for cefoperazone sodium, and were 1.86% and 3.08%, respectively, for sulbactam sodium; and those of FOP were 2.93% and 2.92%, respectively, for cefoperazone sodium, and were 2.23% and 3.01%, respectively, for sulbactam sodium. Based on the ICH guidelines and Ref. 12, the quantitative models were then evaluated in terms of specificity, linearity, accuracy, precision, robustness and model transferability. The non-destructive quantitative NIR methods used in this study are applicable for rapid analysis of injectable powdered drugs from different manufacturers. 展开更多
关键词 NIR diffuse reflectance spectroscopy Non-destructive determination Cefoperazone sodium/sulbactam sodium Injection powder medicament Validation Counterfeit medicine
暂未订购
In vitro activity of moxifloxacin and piperacillin/sulbactam against pathogens of acute cholangitis 被引量:19
3
作者 Andreas Weber Wolfgang Huber +5 位作者 Klaus Kamereck Philipp Winkle Petra Voland Hans Weidenbach Roland M Schmid Christian Prinz 《World Journal of Gastroenterology》 SCIE CAS CSCD 2008年第20期3174-3178,共5页
AIM:To analyze the in vitro activity of moxifloxacin and piperacillin/sulbactam against pathogens isolated from patients with acute cholangitis. METHODS: In this prospective study a total of 65 patients with acute c... AIM:To analyze the in vitro activity of moxifloxacin and piperacillin/sulbactam against pathogens isolated from patients with acute cholangitis. METHODS: In this prospective study a total of 65 patients with acute cholangitis due to biliary stone obstruction (n = 7), benign biliary stricture (n = 16), and malignant biliary stricture (n = 42) were investigated with regard to spectrum of bacterial infection and antibiotic resistance. Pathogens were isolated from bile cultures in all study patients. In 22 febrile patients, blood cultures were also obtained. In vitro activity of moxifloxacin and piperacillin/ sulbactam was determined by agar diffusion. RESULTS: Thirty-one out of 65 patients had positive bile and/or blood cultures. In 31 patients, 63 isolates with 17 different species were identified. The predominant strains were Enterococcus species (26/63), Ecoli (13/63) and Klebsiella species (8/63). A comparable in vitro activity of moxifloxacin and piperacillin/sulbactam was observed for E.coli and Klebsiella species. In contrast, Enterococcus species had higher resistances towards moxifloxacin. Overall bacteria showed antibiotic resistances in vitro of 34.9% for piperacillin/sulbactam and 36.5% for moxifioxacin.CONCLUSION: Enterococcus species, E.co/i and Klebsiella species were the most common bacteria isolated from bile and/or blood from patients with acute cholangitis. Overall, a mixed infection with several species was observed, and bacteria showed a comparable in vitro activity for piperacillin/sulbactam and moxifloxacin. 展开更多
关键词 CHOLANGITIS Acute cholangitis Endoscopy ANTIBIOTICS MOXIFLOXACIN PIPERACILLIN sulbactam Biliarystricture Resistance Bacterial pathogens
暂未订购
Cefoperazone sodium/sulbactam sodium vs piperacillin sodium/tazobactam sodium for treatment of respiratory tract infection in elderly patients 被引量:15
4
作者 Xiao-Xia Wang Cheng-Tai Ma +3 位作者 Yan-Xia Jiang Yun-Jie Ge Fa-Yun Liu Wen-Gang Xu 《World Journal of Clinical Cases》 SCIE 2021年第29期8694-8701,共8页
BACKGROUND Respiratory tract infections in the elderly are difficult to cure and can easily recur,thereby posing a great threat to patient prognosis and quality of life.AIM To investigate the therapeutic effects of di... BACKGROUND Respiratory tract infections in the elderly are difficult to cure and can easily recur,thereby posing a great threat to patient prognosis and quality of life.AIM To investigate the therapeutic effects of different antibiotics in elderly patients with respiratory tract infection.METHODS Seventy-four elderly patients with respiratory tract infection were randomly allocated to a study(n=37;treated with cefoperazone sodium/sulbactam sodium)or control(n=37;treated with piperacillin sodium/tazobactam sodium on the basis of routine symptomatic support)group.Both groups were treated for 7 d.Time to symptom relief(leukocyte recovery;body temperature recovery;cough and sputum disappearance;and rale disappearance time),treatment effect,and laboratory indexes[procalcitonin(PCT),C-reactive protein(CRP),white blood cell count(WBC),and neutrophil percentage(NE)]before and 7 d after treatment and the incidence of adverse reactions were assessed.RESULTS In the study group,the time to WBC normalization(6.79±2.09 d),time to body temperature normalization(4.15±1.08 d),time to disappearance of cough and sputum(6.19±1.56 d),and time to disappearance of rales(6.68±1.43 d)were shorter than those of the control group(8.89±2.32 d,5.81±1.33 d,8.77±2.11 d,and 8.69±2.12 d,respectively;P=0.000).Total effective rate was higher in the study group(94.59%vs 75.68%,P=0.022).Serum PCT(12.89±3.96μg/L),CRP(19.62±6.44 mg/L),WBC(20.61±6.38×10^(9)/L),and NE(86.14±7.21%)levels of the study group before treatment were similar to those of the control group(14.05±4.11μg/L,18.79±5.96 mg/L,21.21±5.59×10^(9)/L,and 84.39±6.95%,respectively)with no significant differences(P=0.220,0.567,0.668,and 0.291,respectively).After 7 d of treatment,serum PCT,CRP,WBC,and NE levels in the two groups were lower than those before treatment.Serum PCT(2.01±0.56μg/L),CRP(3.11±1.02 mg/L),WBC(5.10±1.83×10^(9)/L),and NE(56.35±7.17%)levels were lower in the study group than in the control group(3.29±0.64μg/L,5.67±1.23 mg/L,8.13±3.01×10^(9)/L,and 64.22±8.08%,respectively;P=0.000).There was no significant difference in the incidence of adverse reactions between the groups(7.50%vs 12.50%,P=0.708).CONCLUSION Piperacillin sodium/tazobactam sodium is superior to cefoperazone sodium/sulbactam sodium in the treatment of elderly patients with respiratory tract infection with a similar safety profile. 展开更多
关键词 Cefoperazone sodium sulbactam sodium Piperacillin sodium Tazobactam sodium Respiratory tract infection ELDERLY
暂未订购
Sclerotherapy with Leuprolide and Cefoperazone Sulbactam in the Management of Ovarian Endometriomas under Ultrasound Guidance: A Novel Approach 被引量:1
5
作者 Yazhini Selvaraj 《Advances in Sexual Medicine》 2022年第1期34-46,共13页
<span style="font-family:Verdana;">Endometriosis is an estrogen dependent gynecological disorder, which can occur throughout the reproductive age of women, causing chronic pelvic pain, substantial morb... <span style="font-family:Verdana;">Endometriosis is an estrogen dependent gynecological disorder, which can occur throughout the reproductive age of women, causing chronic pelvic pain, substantial morbidity, and impaired fertility. It is clinically defined as the presence of ectopic endometrium resulting in sustained inflammatory reaction. In India</span><span style="font-family:Verdana;">,</span><span style="font-family:Verdana;"> about 29,000,000 women suffer from endometriosis. Severe pelvic pain and recurrent endometriomas were observed even after surgery. We have conducted aspirations totally in 110 patients in which most of the patients were suffering from Stage III & Stage IV of endometriosis except for 7 patients for whom we have done as primary therapy for endometriomas. Among 110 </span><span style="font-family:Verdana;">patients</span><span style="font-family:;" "=""><span style="font-family:Verdana;">, 4 patients didn’t turn up for follow up after first aspiration. This pilot study conducted with 110 patients in Ponni Hospital and Fertility Research Centre, Madurai aimed to evaluate pregnancy outcome in 51 infertile patients, and to alleviate pelvic pain, to restore a healthy sexual life and to reduce the recurrence rate of Ovarian Endometriomas (OE) in 59 patients, who did not seek fertility, After using the newer sclerosing agent Leuprolide with Cefoperazone Sulbactam (LCS) under ultrasound guidance. This prospective pilot study resulted in a highly significant achievement in pregnancy where 41 patients conceived out of 51 patients (80.39%) only 6 are in ongoing treatment. Those who didn’t seek fertility were 59 of which 43 have </span><span style="font-family:Verdana;">completed family 1</span></span><span style="font-family:Verdana;">3</span><span style="font-family:Verdana;"> have one child</span><span style="font-family:Verdana;"> and 3 unmarried girls</span><span style="font-family:Verdana;">. 96.61% were relieved of pain and recurrence and restored healthy sexual life, 2 are in ongoing treatment. We have not encountered any adverse effects during this</span><span style="font-family:Verdana;"> treatment.</span> 展开更多
关键词 Ovarian Endometriomas (OE) Infertility (IF) Sclerosing Agent (SA) Leuprolide with Cefoperazone sulbactam (LCS) In Vitro Fertilization (IVF)
暂未订购
Study on the Effect of Shuanghuanglian Powder Needle Combined with Cefoperazone and Sulbactam Sodium on Pseudomonas aeruginosa in Vitro 被引量:1
6
作者 Jiming Li Meide Wei +5 位作者 Lili Wang Yanbo Wu Lu Kang Chunchun Su Fengli Yang Guosheng Su 《Advances in Microbiology》 CAS 2023年第5期223-236,共14页
Objective: To explore the antibacterial activity of combined use of Shuanghuanglian and cefoperazone sulbactam sodium on resistant strains of Pseudomonas aeruginosa. Methods: The Pseudomonas aeruginosa strains which w... Objective: To explore the antibacterial activity of combined use of Shuanghuanglian and cefoperazone sulbactam sodium on resistant strains of Pseudomonas aeruginosa. Methods: The Pseudomonas aeruginosa strains which were sensitive and resistant to cefoperazone sulbactam sodium were selected to prepare different test bacterial solutions respectively;The experimental liquid of Shuanghuanglian and Cefoperazone Sulbactam Sodium were prepared separately and set as different test groups and control groups;The Drug Sensitivity Tests of Shuanghuanglian and cefoperazone sulbactam sodium at different concentration gradients which were used alone or used in combination were carried out for different strains with sensitivity and resistance, And use standard entry as a reference control. Result: The results of drug sensitivity test of Shuanghuanglian combined with Cefoperazone-Sulbactam sodium against the resistant strains of Pseudomonas aeruginosa were compared with the results of drug sensitivity test of the two separately used, and the difference was statistically significant (P 〈 0.05) [The drug sensitivity test results of Shuanghuanglian and cefoperazone sulbactam sodium to Pseudomonas aeruginosa resistant strains were statistically significant compared with the drug sensitivity test results of Shuanghuanglian and Cefoperazone Sulbactam Sodium used separately (P 〈 0.05)];There was a dependence between strains and concentration in the effect of the combination of the two drugs. Conclusion: The combination of Shuanghuanglian and cefoperazone sulbactam sodium has synergistic antibacterial or bactericidal effect on Pseudomonas aeruginosa resistant strains. . 展开更多
关键词 Shuanghuanglian Cefoperazone-sulbactam Sodium Use in Combination Pseudomonas aeruginosa Drug Resistance BACTERIOSTASIS
在线阅读 下载PDF
The Study of Effect of Commercial Baicalin Combined with Cefoperazone Sulbactam Sodium on Pseudomonas aeruginosa in Vitro
7
作者 Jiming Li Meide Wei +5 位作者 Linghong Wang Yanbo Wu Lu Kang Yan Tang Huan Zhao Yubiao Sun 《Natural Science》 2022年第3期117-124,共8页
Objective: To investigate the antibacterial effect of baicalin combined with cefoperazone-sulbactam sodium on drug-resistant strains of Pseudomonas aeruginosa. Method: Pseudomonas aeruginosa strains that are sensitive... Objective: To investigate the antibacterial effect of baicalin combined with cefoperazone-sulbactam sodium on drug-resistant strains of Pseudomonas aeruginosa. Method: Pseudomonas aeruginosa strains that are sensitive and resistant to cefoperazone-sulbactam sodium were selected to prepare different test bacterial solutions respectively;The test solutions of baicalin and cefoperazone sulbactam sodium were prepared respectively, and different test groups and control groups were set up;The drug sensitivity tests of different concentration gradients of baicalin and cefoperazone sulbactam sodium used alone and in combination were carried out for different sensitive and drug-resistant strains, and the standard strains were used as parallel control. Result: The drug susceptibility test results of the combined use of baicalin and cefoperazone-sulbactam against Pseudomonas aeruginosa drug-resistant strains were compared with the drug susceptibility results of the two used separately, and the difference was statistically significant (P Pseudomonas aeruginosa. 展开更多
关键词 BAICALIN Cefoperazone-sulbactam Sodium Combined Use Pseudomonas aeruginosa Drug Resistance ANTIBACTERIAL
暂未订购
Clinical Effect and Safety of Western Medicine Cefoperazone Sodium and Sulbactam Sodium
8
作者 XU Xia HU Yudi +1 位作者 HE Yu WEI Jing 《外文科技期刊数据库(文摘版)医药卫生》 2021年第9期017-019,共5页
Objective: to investigate the clinical value of western medicine cefoperazone sodium sulbactam sodium. Methods: the clinical data of patients with inflammation in our hospital were randomly selected, a total of 50 cas... Objective: to investigate the clinical value of western medicine cefoperazone sodium sulbactam sodium. Methods: the clinical data of patients with inflammation in our hospital were randomly selected, a total of 50 cases were divided into a group of 25 cases on average, the control group was treated with ceftazidime, and the observation group was treated with cefoperazone sodium and sulbactam sodium, and the treatment results were analyzed and compared. Results: there was no difference in inflammatory cytokines between the two groups before treatment (P > 0.05). After treatment, the total effective rate of 96% was significantly higher and the level of inflammatory factors was significantly lower in the observation group (P < 0.05). Compared with the treatment period, the incidence of adverse reactions in the control group was higher, the mean time of fever abatement and the time of cough disappearance were longer (P < 0.05). Conclusion: in clinical practice, cefoperazone sodium and sulbactam sodium has good final effect. After medication, it can not only reduce the level of inflammatory factors in patients, improve the prognosis of patients, but also have fewer adverse reactions and good therapeutic effect. Therefore, it can be widely used in clinical treatment. 展开更多
关键词 cefoperazone sodium and sulbactam sodium SECURITY clinical effect western medicine drugs
暂未订购
Comparison of the Clinical Efficacy of Cefoperazone Sulbactam and Ceftazidime in the Treatment of Complicated Urinary Tract Infections
9
作者 LUOHaiping 《外文科技期刊数据库(文摘版)医药卫生》 2022年第10期088-092,共5页
Objective: to compare and analyze the clinical efficacy of cefoperazone sulbactam and ceftazidime in the treatment of complicated urinary tract infections and to provide a theoretical basis for the clinical drug treat... Objective: to compare and analyze the clinical efficacy of cefoperazone sulbactam and ceftazidime in the treatment of complicated urinary tract infections and to provide a theoretical basis for the clinical drug treatment of diseases. Methods: a retrospective study of 140 patients with complicated urinary tract infections admitted to the urology department of Hu’nan Provincial Peoples Hospital from January 2017 to December 2017: cefoperazone sulbactam group (71 patients, 1.0g / bid, 2 g/d) and (69 patients, 1.5g / bid, 3g / d), and PCT, CRP. Results: more cefoperazone subactam (70 / 71,94.29%) than ceftazidime (60 / 69,84.29%) were significant (P < 0.05). A total of 19 strains were detected in the cefoperazone and sulbactam group and 33 strains in the ceftazidime group, with a significant difference in the degree of bacterial clearance in the ceftazidim group (P < 0.05). Between groups, found that the bacterial clearance rate was higher in cefoperazone sulbactam group (84.21%) than in ceftazidime group (72.73%). Plasma PCT, CRP content were decreased compared to before treatment, and the difference between the groups was significant (P < 0.05). After treatment comparison, plasma PCT(0.21±0.15ng/m L) and CRP (0.68±5.24mg/L) content in cefoperazone sulbactam group were lower than those in ceftazidime group (0.87±0.32ng/m L), (20.49±6.81mg/L), and both differences were significant (P < 0.05). The cefoperazone sulbactam group (2.73 ± 0.95 days) and the treatment cost (1078.90 ± 375.44 yuan) were less than the ceftazidime group (6.97 ± 2.25 days) and (1141.69 ± 368.55 yuan), all statistically significant (P < 0.05). The incidence of adverse reactions between cefoperazone and sulbactam (1.40%) and ceftazidime (2.89%) was not significantly different (P > 0.05), and no serious adverse drug reactions occurred. Conclusion: cefoperazone subactam has better efficacy than ceftazidime for complicated urinary tract infections, mainly in bacterial clearance, course control and treatment cost. Patients with cefoperazone subactatan treatment also have better inflammatory status control. 展开更多
关键词 cefoperazone sulbactam CEFTAZIDIME complicated urinary tract infection
暂未订购
头孢哌酮钠舒巴坦钠治疗老年慢性阻塞性肺疾病合并肺部感染患者的疗效及对凝血功能的影响 被引量:2
10
作者 王刚 刘建新 +1 位作者 张峰 林昱 《中国药物应用与监测》 2025年第2期211-214,共4页
目的探讨头孢哌酮钠舒巴坦钠治疗老年慢性阻塞性肺疾病合并肺部感染患者的临床疗效及对凝血功能的影响。方法按随机数字表法将2022年1月至2024年1月中国人民解放军联勤保障部队第九八七医院收治的104例老年慢性阻塞性肺疾病合并肺部感... 目的探讨头孢哌酮钠舒巴坦钠治疗老年慢性阻塞性肺疾病合并肺部感染患者的临床疗效及对凝血功能的影响。方法按随机数字表法将2022年1月至2024年1月中国人民解放军联勤保障部队第九八七医院收治的104例老年慢性阻塞性肺疾病合并肺部感染患者分为两组。对照组52例,男性30例,女性22例,年龄(69.43±7.25)岁,采用头孢他啶治疗。观察组52例,男性28例,女性24例,年龄(69.72±7.19)岁,采用头孢哌酮舒巴坦钠治疗。比较两组临床疗效,凝血功能指标及肺功能指标,统计分析两组不良反应。结果观察组总有效率90.38%(47/52)高于对照组71.15%(37/52)(χ^(2)=6.190,P=0.013)。治疗后观察组和对照组凝血酶原时间、凝血时间、活化部分凝血活酶时间[分别是(14.94±2.15)s、(18.29±2.74)s、(44.32±5.31)s、(10.64±2.26)s、(14.17±2.28)s、(30.47±3.76)s],均高于治疗前[分别是(12.75±2.12)s、(15.51±2.02)s、(32.10±3.53)s、(12.85±2.20)s、(15.38±2.17)s、(32.35±3.88)s],且观察组高于对照组(P<0.05);治疗后观察组和对照组第1秒用力呼气容积(FEV1)、用力肺活量(FVC)及FEV1/FVC水平[分别是(1.59±0.25)L、(2.24±0.34)L、(78.32±8.31)%、(1.38±0.26)L、(1.97±0.28)L、(65.32±7.76)%],且观察组水平高于对照组,两组治疗后均高于治疗前[分别是(1.14±0.22)L、(1.62±0.23)L、(61.32±7.19)%、(1.17±0.23)L、(1.59±0.25)L、(60.47±7.47)%],差异均具有统计学意义(均P<0.05)。结论头孢哌酮钠舒巴坦钠治疗老年慢性阻塞性肺疾病合并肺部感染的临床疗效较好,能有效改善患者肺功能,虽然对凝血功能有一定影响但仍在可控范围内。 展开更多
关键词 慢性阻塞性肺疾病 肺部感染 老年 头孢哌酮钠舒巴坦钠 临床疗效 凝血功能
暂未订购
舒巴坦-度洛巴坦用于肺移植术后抗感染治疗
11
作者 王璐琳 王晓华 +3 位作者 张婕 周守宁 喻鹏玖 巨春蓉 《器官移植》 北大核心 2025年第5期756-762,共7页
目的总结国内首例舒巴坦-度洛巴坦治疗肺移植术后广泛耐药鲍曼不动杆菌感染的临床经验。方法回顾1例重度慢性阻塞性肺疾病患者肺移植术后接受舒巴坦-度洛巴坦治疗的病例。结果68岁男性,术前有耐药鲍曼不动杆菌感染史,术后感染加重伴肾... 目的总结国内首例舒巴坦-度洛巴坦治疗肺移植术后广泛耐药鲍曼不动杆菌感染的临床经验。方法回顾1例重度慢性阻塞性肺疾病患者肺移植术后接受舒巴坦-度洛巴坦治疗的病例。结果68岁男性,术前有耐药鲍曼不动杆菌感染史,术后感染加重伴肾功能受损,痰培养为广泛耐药鲍曼不动杆菌。在接受舒巴坦-度洛巴坦联合美罗培南治疗后,感染得到控制,移植肺功能恢复。结论舒巴坦-度洛巴坦对肺移植术后广泛耐药鲍曼不动杆菌感染具有潜在治疗价值,为临床提供了新策略。 展开更多
关键词 舒巴坦-度洛巴坦 肺移植 感染 慢性阻塞性肺疾病 革兰阴性杆菌 广泛耐药鲍曼不动杆菌 美罗培南 重症监护室
暂未订购
替加环素联合头孢哌酮/舒巴坦治疗多重耐药鲍曼不动杆菌肺炎的临床疗效
12
作者 吉家兴 姜晓杰 杨妍 《临床肺科杂志》 2025年第2期195-199,208,共6页
目的基于细菌清除率、炎症因子、安全性探究替加环素(TGC)联合头孢哌酮/舒巴坦(CPZ/SBT)治疗多重耐药鲍曼不动杆菌(MRAB)肺炎的作用。方法回顾性收集2022年1月至2023年6月期间在本院治疗的156例MRAB肺炎患者的临床资料,经1∶1倾向性评... 目的基于细菌清除率、炎症因子、安全性探究替加环素(TGC)联合头孢哌酮/舒巴坦(CPZ/SBT)治疗多重耐药鲍曼不动杆菌(MRAB)肺炎的作用。方法回顾性收集2022年1月至2023年6月期间在本院治疗的156例MRAB肺炎患者的临床资料,经1∶1倾向性评分匹配后,CPZ/SBT组50例和TGC+CPZ/SBT组各纳入50例。CPZ/SBT组给予头孢哌酮/舒巴坦治疗,TGC+CPZ/SBT组给予头孢哌酮/舒巴坦+替加环素治疗。检测并比较两组患者用药前后的痰液相关指标[嗜酸性粒细胞(Eos)和中性粒细胞(Neu)]、血清炎性标志物[白介素-6(IL-6)、C-反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)和降钙素原(PCT)],并对两组体征/症状改善时间、疗效总有效率、不良反应发生率、脱机成功率、细菌清除率、住院时间和28d死亡率进行比较,采用Spearman检验方法分析MRAB肺炎患者炎症相关指标与疗效总有效率之间的相关性。结果TGC+CPZ/SBT组患者体温变为正常、胸片阴影与肺部啰音消失、白细胞变为正常的时间相较于CPZ/SBT组明显缩短(P均<0.05)。TGC+CPZ/SBT组疗效总有效率以及细菌清除率显著高于CPZ/SBT组(94.00%vs 80.00%、90.00%vs 74.00%,P<0.05)。用药后,两组CRP、TNF-α、PCT、IL-6、Neu、Eos较用药前显著降低(P均<0.05),TGC+CPZ/SBT组CRP、TNF-α、PCT、IL-6、Neu、Eos明显低于CPZ/SBT组(P均<0.05)。TGC+CPZ/SBT组患者住院时间相较于CPZ/SBT组明显减少[(29.36±7.11)d vs(33.67±8.25)d,P<0.05],而TGC+CPZ/SBT组患者的脱机成功率较CPZ/SBT组明显提高(80.00%vs 60.00%,P<0.05),两组28d死亡率以及不良反应发生率差异无统计学意义(6.00%vs 16.00%,18.00%vs 10.00%,P均>0.05)。Spearman检验结果显示,治疗后血清CRP、TNF-α、PCT、IL-6及痰液Neu、Eos水平与TGC+CPZ/SBT组患者疗效总有效率呈负相关(r=-0.521、-0.425、-0.556、-0.463、-0.512、-0.488,P均<0.001)。结论MRAB肺炎患者采用替加环素联合CPZ/SBT治疗有助于提高疗效总有效率以及细菌清除率,降低体内炎症水平,安全性良好。 展开更多
关键词 替加环素 头孢哌酮/舒巴坦 多重耐药鲍曼不动杆菌肺炎 细菌清除率 炎症因子 安全性
暂未订购
盐酸小檗碱联合头孢哌酮舒巴坦对碳青霉烯类耐药铜绿假单胞菌生物膜的作用
13
作者 黄双旺 潘菲 +1 位作者 杨游萍 苏歆 《广东医学》 2025年第1期27-32,共6页
目的研究盐酸小檗碱(berberine hydrochloride,BBH)联合头孢哌酮舒巴坦(cefoperazone sulbactam,CSL)对碳青霉烯类耐药铜绿假单胞菌(carbapenem resistant Pseudomonas aeruginosa,CRPA)生物膜形成的抑制作用。方法选取分离自临床的10株... 目的研究盐酸小檗碱(berberine hydrochloride,BBH)联合头孢哌酮舒巴坦(cefoperazone sulbactam,CSL)对碳青霉烯类耐药铜绿假单胞菌(carbapenem resistant Pseudomonas aeruginosa,CRPA)生物膜形成的抑制作用。方法选取分离自临床的10株CPRA,采用微量肉汤稀释法和棋盘微量稀释法,分别测定BBH和CSL单用和联合用药对CRPA的最低抑菌浓度(minimum inhibitory concentration,MIC),并计算联合抑菌浓度指数(fractional inhibitory concentration index,FICI)。应用结晶紫染色半定量法筛选产生物膜菌株。进一步选择PA110菌株,检测BBH联合CSL对其生物膜形成抑制作用和预先形成生物膜消除作用。结果BBH对CRPA的MIC范围在512~2048 mg/L,CSL对CRPA的MIC范围在4~128 mg/L;BBH联合CSL使用的FICI范围在0.268~0.625,4株菌为协同作用,6株菌为相加作用。10株菌均产生生物膜,1株弱阳性,6株阳性,3株强阳性;PA110菌株生物膜强阳性,吸光度值X(1.145),为产生物膜最强菌株。在生物膜抑制实验中,BBH组中BBH浓度为512 mg/L时抑膜率为50.7%;CSL组中CSL浓度为1 mg/L时抑膜率为62.8%;联合用药组中,抑膜率为88.2%,联合用药抑膜率显著高于单药组,差异有统计学意义(P<0.01)。在预先形成生物膜消除实验中,BBH组中浓度为512mg/L时抑膜率为44.5%;CSL组中浓度为1 mg/L时抑膜率为56.7%;联合用药组中抑膜率为80.9%。联合用药消膜率显著高于单药组,差异有统计学意义(P<0.01)。结论BBH联合CSL能有效提高单药对CRPA的抑菌活性,抑制和消除生物膜的形成,为临床治疗CRPA提供新的可能和依据。 展开更多
关键词 盐酸小檗碱 头孢哌酮-舒巴坦 碳青霉烯类耐药铜绿假单胞菌 生物膜
暂未订购
头孢哌酮钠舒巴坦钠致危重症患者凝血功能障碍46例报告
14
作者 董漪竹 蔡丽萍 +2 位作者 梁建敏 韩一波 黄贻富 《中国药物应用与监测》 2025年第3期558-562,共5页
目的探讨头孢哌酮钠舒巴坦钠(cefoperazone sodium and sulbactam sodium,CSSS)致危重症患者凝血功能障碍的因素,为制订预防该类不良反应策略提供依据。方法采用回顾性研究法选取2022年12月至2024年5月在北海市人民医院急诊重症监护室... 目的探讨头孢哌酮钠舒巴坦钠(cefoperazone sodium and sulbactam sodium,CSSS)致危重症患者凝血功能障碍的因素,为制订预防该类不良反应策略提供依据。方法采用回顾性研究法选取2022年12月至2024年5月在北海市人民医院急诊重症监护室、重症医学科使用头孢哌酮钠舒巴坦钠治疗出现相关凝血功能障碍的患者46例,统计患者年龄、性别、用药前肝肾功能情况、用药剂量以及用药前后国际标准比值(international normalized ratio,INR)、凝血酶原时间(PT)、血小板数目(PLT)、血清天冬氨酸氨基转移酶(AST)、血清丙氨酸氨基转移酶(ALT)、血清γ-谷氨酰基转移酶(GGT)、血清碱性磷酸酶(AKP)、血清总胆红素(TBIL)、血清直接胆红素(DBIL)、血清间接胆红素测定(IDBIL)、血清白蛋白(ALB)、肌酐(CREA)、尿素(UREA)指标变化以及患者用药前疾病。结果46例患者中男性35例(76.09%),女性11例(23.91%),60岁以上的老年人41例(89.13%);用药前肝和/或肾检查异常的患者多于正常患者(χ^(2)=44.522,P<0.05);患者用药后的INR、PT、AST、GGT、CREA、UREA水平均高于用药前(t=-21.123、-20.771、-11.997、-20.360、-9.219、-12.594,均P<0.05);PLT、ALT、AKP、TBIL、IDBIL、ALB水平均低于用药前(t=10.907、2.799、2.417、5.880、9.260、9.700,均P<0.05);用药前、后的DBIL水平比较无统计学意义(t=1.033,P=0.305)。结论本研究中CSSS致危重症患者凝血功能障碍的主要因素为老年人、男性、用药前肝肾功能情况、患者用药情况,CSSS不仅会引起危重症患者的凝血功能障碍,还会加重肝肾的损伤,临床用药时需密切监测凝血功能和肝肾功能指标。 展开更多
关键词 头孢哌酮钠舒巴坦钠 重症 凝血功能障碍 危险因素 不良反应
暂未订购
头孢哌酮钠舒巴坦钠在敏感细菌感染性疾病治疗中的药学效果
15
作者 郭胜杰 王宇 《系统医学》 2025年第12期181-184,共4页
目的评价头孢哌酮钠舒巴坦钠治疗敏感细菌感染性疾病的药学效果。方法目的选取2022年3月—2024年3月四平市中心人民医院收治的200例敏感细菌感染性疾病患者为研究对象。依据不同用药方案分为2组(对照组和观察组),每组100例。对照组以头... 目的评价头孢哌酮钠舒巴坦钠治疗敏感细菌感染性疾病的药学效果。方法目的选取2022年3月—2024年3月四平市中心人民医院收治的200例敏感细菌感染性疾病患者为研究对象。依据不同用药方案分为2组(对照组和观察组),每组100例。对照组以头孢他啶治疗,观察组以头孢哌酮钠舒巴坦钠治疗。比较两组患者临床症状消退时间、炎性因子水平、临床治疗效果及不良反应发生情况。结果观察组肺啰音、咳嗽、发热的消退时间分别为(5.08±1.32)d、(5.05±1.22)d、(5.63±1.25)d比对照组的(7.25±1.49)d、(7.27±1.58)d、(7.38±1.81)d更短,差异均有统计学意义(t=10.901,10.971,7.956;P均<0.05)。且观察组治疗后炎性因子水平低于对照组,差异均有统计学意义(P均<0.05)。观察组治疗总有效率为96.00%(96/100)优于对照组的82.00%(82/100),差异有统计学意义(χ^(2)=10.010,P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论头孢哌酮钠舒巴坦钠可快速消退敏感细菌感染性疾病患者的临床症状,治疗效果良好,同时还可降低炎症水平,具有一定的安全性。 展开更多
关键词 头孢哌酮钠舒巴坦钠 敏感细菌感染性疾病 临床症状 炎性因子 不良反应
暂未订购
头孢哌酮舒巴坦治疗脑卒中并发肺炎临床观察
16
作者 张华 郭情情 +1 位作者 苏奕亮 翁东 《中国药业》 2025年第3期93-96,共4页
目的探讨头孢哌酮舒巴坦治疗脑卒中并发肺炎的临床疗效,以及对患者氧化应激指标、氨基末端脑利钠肽前体(NT-proBNP)及Toll样受体(TLR)水平的影响。方法回顾性分析山东省淄博市中心医院东院2021年3月至2023年3月收治的106例脑卒中并发肺... 目的探讨头孢哌酮舒巴坦治疗脑卒中并发肺炎的临床疗效,以及对患者氧化应激指标、氨基末端脑利钠肽前体(NT-proBNP)及Toll样受体(TLR)水平的影响。方法回顾性分析山东省淄博市中心医院东院2021年3月至2023年3月收治的106例脑卒中并发肺炎患者的临床资料,按治疗方案的不同分为常规组(47例)和干预组(59例)。两组患者均予常规营养神经、抗感染治疗,在此基础上,常规组患者加用头孢他啶,干预组患者加用头孢哌酮舒巴坦,两组患者均连续治疗2周。结果干预组总有效率为89.83%,显著高于常规组的68.09%(P<0.05)。治疗后,干预组患者的细菌清除率为86.44%,显著高于对照组的68.09%(P<0.05);两组患者的丙二醛、降钙素原、白细胞介素6、脂质过氧化氢、C反应蛋白、TLR、NT-proBNP水平均显著降低(P<0.05),超氧化物歧化酶水平均显著升高(P<0.05),且干预组均显著优于常规组(P<0.05)。干预组和常规组患者不良反应发生率相当(6.78%比6.38%,P>0.05)。结论头孢哌酮舒巴坦治疗脑卒中并发肺炎的临床疗效良好,可有效降低患者的TLR和NT-proBNP水平,减轻炎性反应和氧化应激反应,且安全性良好。 展开更多
关键词 头孢哌酮舒巴坦 脑卒中并发肺炎 氧化应激反应 氨基末端脑利钠肽前体 TOLL样受体
暂未订购
匹多莫德联合头孢哌酮钠舒巴坦钠对产超广谱β-内酰胺酶菌所致复杂性尿路感染患者微生物清除率、尿路症状及复发率的影响
17
作者 尹剑辉 岳永俊 靳丰 《西北药学杂志》 2025年第6期253-258,共6页
目的探讨匹多莫德联合头孢哌酮钠舒巴坦钠对产超广谱β-内酰胺酶(extended-spectrumβ-Lactamases,ESBLs)菌所致复杂性尿路感染(complicated urinary tract infection,cUTI)患者微生物清除率、尿路症状改善及复发率的影响。方法纳入2021... 目的探讨匹多莫德联合头孢哌酮钠舒巴坦钠对产超广谱β-内酰胺酶(extended-spectrumβ-Lactamases,ESBLs)菌所致复杂性尿路感染(complicated urinary tract infection,cUTI)患者微生物清除率、尿路症状改善及复发率的影响。方法纳入2021年6月至2024年6月收治的产ESBLs菌所致cUTI患者378例,按随机数字表法分为常规组(予以头孢哌酮钠舒巴坦钠治疗)和联合组(予以匹多莫德联合头孢哌酮钠舒巴坦钠治疗),各189例。比较2组的临床疗效、微生物清除率及治疗前后的尿路症状评分、尿常规指标[尿白细胞数,亚硝酸盐(nitrite,NIT)阳性率,尿白细胞酯酶(leukocyte esterase,LEU)阳性率]、免疫功能指标[CD4^(+)/CD8^(+)、免疫球蛋白A(immunoglobulin A,IgA)、免疫球蛋白M(immunoglobulin M,IgM)、免疫球蛋白G(immunoglobulin G,IgG)]水平,统计2组不良反应发生率以及随访6个月的复发情况。结果联合组的总有效率(94.71%)高于常规组(88.89%),差异具有统计学意义(P<0.05);联合组的微生物清除率(87.30%)高于常规组(79.37%),差异具有统计学意义(P<0.05);治疗10 d后,2组的尿急、尿痛、尿频症状均改善,且联合组的改善情况优于常规组,差异具有统计学意义(P<0.05);2组尿白细胞数、NIT阳性率及LEU阳性率均降低,且联合组均低于常规组,差异具有统计学意义(P<0.05);2组的CD4^(+)/CD8^(+)、IgA、IgM及IgG水平均升高,且联合组均高于常规组,差异具有统计学意义(P<0.05);2组总不良反应发生率比较差异无统计学意义(P>0.05),联合组的复发率低于常规组,差异具有统计学意义(P<0.05)。结论匹多莫德联合头孢哌酮钠舒巴坦钠治疗产ESBLs菌所致cUTI患者的疗效显著,能改善患者的微生物清除率、尿路症状、尿常规指标及免疫功能指标水平,并降低cUTI的复发率,且安全性良好。 展开更多
关键词 匹多莫德 头孢哌酮钠舒巴坦钠 产超广谱Β-内酰胺酶菌 复杂性尿路感染 微生物清除率
暂未订购
左氧氟沙星联合头孢哌酮钠舒巴坦钠对细菌性肺炎的用药效果及安全性评估
18
作者 马涛 李小阳 魏新苗 《中国实用医药》 2025年第9期75-78,共4页
目的对左氧氟沙星、头孢哌酮钠舒巴坦钠联合治疗细菌性肺炎的效果进行分析,并评估用药安全性。方法50例细菌性肺炎患者为研究对象,随机分为观察组(n=25)、对照组(n=25)。对照组行头孢哌酮钠舒巴坦钠治疗,观察组行左氧氟沙星联合头孢哌... 目的对左氧氟沙星、头孢哌酮钠舒巴坦钠联合治疗细菌性肺炎的效果进行分析,并评估用药安全性。方法50例细菌性肺炎患者为研究对象,随机分为观察组(n=25)、对照组(n=25)。对照组行头孢哌酮钠舒巴坦钠治疗,观察组行左氧氟沙星联合头孢哌酮钠舒巴坦钠治疗。比较两组治疗效果、不良反应发生率、肺功能。结果观察组患者治疗总有效率96.0%高于对照组的76.0%(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。治疗前,两组患者第1秒用力呼气容积、用力肺活量比较差异无统计学意义(P>0.05);治疗后,两组患者第1秒用力呼气容积、用力肺活量均高于本组治疗前,且观察组患者第1秒用力呼气容积(2.33±0.28)L、用力肺活量(3.29±0.41)L均明显高于对照组的(2.15±0.26)、(2.94±0.42)L(P<0.05)。结论左氧氟沙星联合头孢哌酮钠舒巴坦钠治疗细菌性肺炎效果理想,患者的治疗有效率较高,肺部功能的改善也更明显,且安全可靠,患者不良反应发生率没有显著增长,未来工作中可重视该方案的运用、推广。 展开更多
关键词 左氧氟沙星 头孢哌酮钠舒巴坦钠 细菌性肺炎 用药效果 安全性
暂未订购
阿米卡星联合头孢哌酮钠舒巴坦钠治疗铜绿假单胞菌肺炎的临床观察
19
作者 赵宏巧 《医药论坛杂志》 2025年第11期1221-1224,共4页
目的观察阿米卡星联合头孢哌酮钠舒巴坦钠治疗铜绿假单胞菌肺炎(pseudomonas aeruginosa pneumonia,PAP)的效果。方法回顾河南科技大学第一附属医院2021年6月—2023年7月104例PAP患者资料,根据治疗方案不同分为对照组(头孢哌酮钠舒巴坦... 目的观察阿米卡星联合头孢哌酮钠舒巴坦钠治疗铜绿假单胞菌肺炎(pseudomonas aeruginosa pneumonia,PAP)的效果。方法回顾河南科技大学第一附属医院2021年6月—2023年7月104例PAP患者资料,根据治疗方案不同分为对照组(头孢哌酮钠舒巴坦钠治疗,n=48)和观察组(阿米卡星联合头孢哌酮钠舒巴坦钠治疗,n=56),均完成6 d治疗。比较两组炎症指标(白细胞计数、C反应蛋白、降钙素原)、症状改善时间及病原菌清除情况,统计不良反应情况。结果治疗后,两组白细胞计数、C反应蛋白、降钙素原有所降低,且观察组更低,差异有统计学意义(P<0.05)。观察组咳嗽、咳痰及发热改善时间短于对照组,差异有统计学意义(P<0.05)。观察组病原菌清除率(91.07%)高于对照组(66.67%)(χ^(2)=9.552,P=0.002)。治疗期间,两组不良反应发生率比较,差异无统计学意义(P=0.373)。结论阿米卡星与头孢哌酮舒巴坦钠联合治疗PAP能显著减轻炎症,缩短其症状缓解时间,提高病原菌清除率,且不增加安全隐患。 展开更多
关键词 肺炎 铜绿假单胞菌 头孢哌酮钠舒巴坦钠 阿米卡星 不良反应
原文传递
舒巴坦度洛巴坦治疗耐碳青霉烯类鲍曼不动杆菌肺部感染的临床效果及药物浓度监测
20
作者 陈玥 乔琳 +3 位作者 谢众垚 陈文倩 郭冬杰 李朋梅 《中华医院感染学杂志》 北大核心 2025年第20期3105-3109,共5页
目的探讨舒巴坦度洛巴坦联合美罗培南治疗碳青霉烯耐药的鲍曼不动杆菌(CRAB)肺部感染的疗效。方法纳入中日友好医院2025年1月1日-6月1日治疗的16例患者,回顾性分析患者基本情况、前期治疗方案、与感染治疗相关诊断和病原学及临床转归情... 目的探讨舒巴坦度洛巴坦联合美罗培南治疗碳青霉烯耐药的鲍曼不动杆菌(CRAB)肺部感染的疗效。方法纳入中日友好医院2025年1月1日-6月1日治疗的16例患者,回顾性分析患者基本情况、前期治疗方案、与感染治疗相关诊断和病原学及临床转归情况,并对舒巴坦进行了治疗药物监测。结果13例患者在疗程结束时达到CRAB病原学清除和临床好转,1例患者在一个月内出现CRAB复发。3例患者治疗失败。13例患者进行了舒巴坦的治疗药物监测,除1例患者略低外,均达到血药谷浓度在最小抑菌浓度(MIC)之上(100%T>MIC,按临床折点计算,MIC=4 mg/L)。4例患者根据血药浓度调整剂量,3例减量,1例增加剂量。结论舒巴坦度洛巴坦联合美罗培南治疗CRAB疗效显著。该药在说明书用法用量下,患者均可达到舒巴坦PK/PD目标。 展开更多
关键词 碳青霉烯类耐药的鲍曼不动杆菌 肺部感染 舒巴坦 舒巴坦度洛巴坦 血药浓度监测
原文传递
上一页 1 2 83 下一页 到第
使用帮助 返回顶部